Reports
Sale
Global Arthralgia Management Market Size, Share, Trends, Report: By Drug Class: Drug, NSAIDs, Corticosteroids, Hyaluronic Acid Injection, Other Drugs; By Treatment: Knee and Ankle Pain, Hip Pain, Shoulder and Elbow Pain, Others; By Distribution Channel; Regional Analysis; Patent Analysis; Grants Analysis; Supplier Landscape; 2024-2032
Global Arthralgia Management Market Outlook
The global arthralgia management market size was valued at USD 6 billion in 2023, driven by the emphasis on developing effective treatments to lower down arthritis cases across the globe. The market is expected to grow at a CAGR of 9.1% during the forecast period of 2024-2032, with the values likely to rise from USD 6.5 billion in 2024 to USD 13 billion by 2032.
Arthralgia Management: Introduction
Arthralgia refers to pain and discomfort in one or multiple joints. It is not a disease, but a symptom of an underlying disease called arthritis. Arthritis causes joint inflammation, which in turn, can lead to joint pain and stiffness. Common areas of pain include hands, arms, shoulders, back, feet, knees, pelvis, and hip bones. Arthralgia can affect one’s ability to perform day to day activities and may interfere with the sleep cycle as well.
Arthralgia treatment constitutes pain relievers in the form of ointments or drugs, surgery and therapies like exercise, joint mobilization, acupuncture, and dietary supplements.
Global Arthralgia Management Market Analysis
Musculoskeletal symptoms like myalgia, arthralgia, backache, and generalized body ache are not commonly associated with coronavirus-related diseases like pneumonia, however, around 30% of the patients hospitalized with the coronavirus reported a musculoskeletal issue. Arthralgia was one of the most severely painful symptoms that coincided with other respiratory issues. Therefore, there has been a significant arthralgia management market growth during the historical period, especially during the COVID-19 pandemic.
Chronic pain is the key characteristic of arthralgia. Mild pain relievers, nonsteroidal anti-inflammatory drugs, corticosteroids are some of the most common treatments available. However, to combat more severe and persistent pains, researchers have been working on new technologies as well. For instance, nanotechnology-based drugs have shown positive results in pain control with limited side effects. Some nanotechnology-based tools can also help in accurate pain measurement, which can help with diagnostics and improve the efficiency of different treatments.
With a deeper understanding of pain inducing electric signals in the nervous system, there are new devices that work with a neuromodulation approach. Such devices include peripheral and spinal stimulators that treat complex pain syndromes by sending electrical impulses to reverse pathologic neural processes. Clinical evidence also supports the treatment. As we progress further into the future, new technologies are set to enter the market. This indicates that arthralgia management market value is likely to grow significantly in the coming years.
Global Arthralgia Management Market Segmentation
Market Breakup by Drug Class
- Drug
- NSAIDs
- Corticosteroids
- Hyaluronic Acid Injection
- Other Drugs
Market Breakup by Treatment
- Knee and Ankle Pain
- Hip Pain
- Shoulder and Elbow Pain
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Arthralgia Management Market Overview
With increasing rates of obesity and injury, arthritis cases are expected to rise globally. The prevalence of obesity among adults in the American region (north, central, and south) is predicted to reach around 47% to 49% by 2035 , affecting nearly half of the population. Similar trend is followed by the European region, where obesity is predicted to affect 35% of the women and 39% of the men . As obesity is a major cause of osteoarthritis, the demand for arthralgia management is expected to grow in the American and European region during the forecast period.
Arthritis is one of the most common diseases associated with an aging population. As the Asian region accounts for most of the world’s geriatric population, the arthralgia management market share is anticipated to observe an exponential growth in this territory as well, converse to the North America holding a big market share in the historical period.
Global Arthralgia Management Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Sanofi
- AstraZeneca
- Johnson & Johnson
- GlaxoSmithKline PLC (UK)
- Bayer AG
- Abbott
- Pfizer, Inc.
- Mylan N.V
- Teva Pharmaceuticals
- Novartis AG
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Treatment |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Arthralgia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Arthralgia Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Arthralgia Epidemiology (2016-2031)
5.3 Europe Arthralgia Epidemiology (2016-2031)
5.4 Asia-Pacific Arthralgia Epidemiology (2016-2031)
5.5 Latin America Arthralgia Epidemiology (2016-2031)
5.6 Middle East & Africa Arthralgia Epidemiology (2016-2031)
6 Global Arthralgia Management Market Overview
6.1 Global Arthralgia Management Market Historical Value (2017-2023)
6.2 Global Arthralgia Management Market Forecast Value (2024-2032)
7 Global Arthralgia Management Market Landscape
7.1 Global Arthralgia Management: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Arthralgia Management: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Diagnosis
7.2.3 Analysis by Application
8 Global Arthralgia Management Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Global Arthralgia Management Market Segmentation
9.1 Global Arthralgia Management Market by Drug Class
9.1.1 Market Overview
9.1.2 Drug
9.1.3 NSAIDs
9.1.4 Corticosteroids
9.1.5 Hyaluronic Acid Injection
9.1.6 Other Drugs
9.2 Global Arthralgia Management Market by Treatment
9.2.1 Market Overview
9.2.2 Knee and Ankle Pain
9.2.3 Hip Pain
9.2.4 Shoulder and Elbow Pain
9.2.5 Others
9.3 Global Arthralgia Management Market by Distribution Channel
9.3.1 Market Overview
9.3.2 Hospital Pharmacies
9.3.3 Retail Pharmacies
9.3.4 Online Pharmacies
9.4 Global Arthralgia Management Market by Region
9.4.1 Market Overview
9.4.2 North America
9.4.3 Europe
9.4.4 Asia Pacific
9.4.5 Latin America
9.4.6 Middle East and Africa
10 North America Arthralgia Management Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Arthralgia Management Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Arthralgia Management Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Arthralgia Management Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Arthralgia Management Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Sanofi
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 AstraZeneca
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Johnson & Johnson
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 GlaxoSmithKline PLC (UK)
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Bayer AG
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Abbott
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Pfizer, Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Mylan N.V
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Teva Pharmaceuticals
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Novartis AG
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 6 billion in 2023, driven by the emphasis to reduce the number of patients suffering from arthritis by developing effective, accurate and high-tech treatments to ease out pain.
The market is anticipated to grow at a CAGR of 9.1% during the forecast period of 2024-2032, likely to reach a market value of USD 13 billion by 2032.
Arthralgia has been a common side effect observed in most of the COVID-19 infected patients. There has been significant emphasis on developing quality treatments to help patients ease out the pain. This has led to high market demand.
Introduction of new technological advancements in the medical industry like nanotechnology-based drugs and devices, along with neuromodulator pain analgesic treatments, are some of the major market trends observed.
Arthralgia treatments are used for knee and ankle pain, hip pain, shoulder and elbow pain, among others.
Arthralgia management drug classes include drugs, NSAIDS, corticosteroids, and hyaluronic acid injection, among other drugs.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
The major distribution channels in the market are hospitals pharmacies, retail pharmacies and online pharmacies.
Key players involved in the market are Sanofi, AstraZeneca, Johnson & Johnson, GlaxoSmithKline PLC (UK), Bayer AG, Abbott, Pfizer, Inc., Mylan N.V, Teva Pharmaceuticals, and Novartis AG.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER